STOCK TITAN

Cannabix Technologies Commences First Production of BreathLogix Alcohol Screening Devices

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags

Cannabix Technologies (OTC:BLOZF) has initiated its first production run of BreathLogix alcohol screening devices, partnering with Price Electronics as their contract manufacturer. Price Electronics, with their 28,000 square foot facility in Winnipeg, brings significant credentials including ISO 13485, ISO9001, and IPC certifications.

The BreathLogix "Workplace Series" device has received National Highway Traffic Safety Association approval and has been added to the U.S. Federal Register Conforming Products List for breath alcohol screening devices. Additionally, the company has secured an exclusive distribution agreement with Breathalyser Sales & Service Pty Ltd. for Australia, New Zealand, and the Pacific Islands.

Loading...
Loading translation...

Positive

  • Secured NHTSA approval for BreathLogix Workplace Series device
  • Partnership with ISO-certified contract manufacturer Price Electronics
  • Exclusive distribution agreement secured for Australia, New Zealand, and Pacific Islands
  • Manufacturing facility offers scalable production capabilities

Negative

  • No current sales of breathalyzers
  • Product still in initial production phase
  • Multiple regulatory and market uncertainties highlighted in forward-looking statements

News Market Reaction 1 Alert

+7.17% News Effect

On the day this news was published, BLOZF gained 7.17%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to report that it has directed Price Electronics to begin manufacturing BreathLogix alcohol screening device components for an initial commercial production run.

The Company recently selected Price Industries Ltd. (“Price Electronics”) as contract manufacture for its BreathLogix alcohol screening device product lines because they are a well-established contract manufacturer with ISO 13485 (medical devices qualifications), ISO9001 and IPC certifications. Price Electronics has a 28,000 square foot manufacturing facility located in Winnipeg, MB, that can cost-effectively support a full range of production volumes and product technologies with scalability.

The Company has provided Price Electronics specifications and tolerances for its BreathLogix alcohol screening device and Price Electronics has begun manufacturing components for assembly and quality control by Cannabix.

The BreathLogix “Workplace Series” device was approved by National Highway Traffic Safety Association (in the United States) to be added to the U.S. Federal Register Conforming Products List (CPL) for breath alcohol screen devices.

The Company recently entered into an exclusive distribution and sales agreement with Breathalyser Sales & Service Pty Ltd., for Australia, New Zealand and the Pacific Islands.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com 

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the distribution and sales agreement with any third-party companies; positive developments with contract manufacturers; the completion of pre-validation or validation testing; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors and or contract manufacturers; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company’s development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.


FAQ

When did Cannabix Technologies (BLOZF) begin production of BreathLogix alcohol screening devices?

Cannabix Technologies initiated the first production run of BreathLogix alcohol screening devices in July 2025 through their contract manufacturer Price Electronics.

Who is manufacturing the BreathLogix devices for Cannabix Technologies?

Price Electronics, an ISO 13485, ISO9001, and IPC certified contract manufacturer with a 28,000 square foot facility in Winnipeg, MB, is manufacturing the BreathLogix alcohol screening devices.

Has the BreathLogix alcohol screening device received any regulatory approvals?

Yes, the BreathLogix 'Workplace Series' device has been approved by the National Highway Traffic Safety Association and added to the U.S. Federal Register Conforming Products List for breath alcohol screening devices.

What distribution agreements does Cannabix Technologies have for BreathLogix?

Cannabix has secured an exclusive distribution and sales agreement with Breathalyser Sales & Service Pty Ltd. for Australia, New Zealand, and the Pacific Islands regions.

Is Cannabix Technologies currently selling breathalyzers?

No, according to the press release, Cannabix is not currently selling breathalyzers, and there is no assurance that the company will do so in the future.
Cannabix Technol

OTC:BLOZF

BLOZF Rankings

BLOZF Latest News

BLOZF Stock Data

48.43M
108.58M
10.32%
Medical Devices
Healthcare
Link
Canada
Burnaby